E Jabbour

Summary

Affiliation: The University of Texas
Country: USA

Publications

  1. request reprint
    Jabbour E, Soverini S. Understanding the role of mutations in therapeutic decision making for chronic myeloid leukemia. Semin Hematol. 2009;46:S22-6 pubmed
    ..The choice of therapy should be guided by multiple factors, including mutational analysis, disease phase, patient characteristics, and the safety profile of the agents. ..
  2. Jabbour E, Kantarjian H, Ghanem H, O Brien S, Quintas Cardama A, Garcia Manero G, et al. The achievement of a 3-month complete cytogenetic response to second-generation tyrosine kinase inhibitors predicts survival in patients with chronic phase chronic myeloid leukemia after imatinib failure. Clin Lymphoma Myeloma Leuk. 2013;13:302-6 pubmed publisher
    ..The achievement of a 3-month CCyR is the only predictor of outcome in patients treated with 2nd-TKI therapy after imatinib failure. Patients with <3-month CCyR may not obtain long-term benefit and should be followed-up closely. ..
  3. Jabbour E, Kantarjian H, Cortes J. Use of second- and third-generation tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia: an evolving treatment paradigm. Clin Lymphoma Myeloma Leuk. 2015;15:323-34 pubmed publisher
    ..Finally, we present 3 case studies to illustrate how prognostic factors and other considerations (eg, tolerability) can be used to individualize subsequent therapy in cases of TKI resistance or intolerance. ..
  4. Jabbour E, Kantarjian H, Ravandi F, Thomas D, Huang X, Faderl S, et al. Combination of hyper-CVAD with ponatinib as first-line therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia: a single-centre, phase 2 study. Lancet Oncol. 2015;16:1547-1555 pubmed publisher
    ..New strategies, including dosing titration of ponatinib and optimised control of vascular risk factors, might further improve outcomes. ARIAD Pharmaceuticals Inc. ..
  5. Jabbour E, Makenbaeva D, Lingohr Smith M, Lin J. Use of Real-World Claim Databases to Assess Prevalence of Comorbid Conditions Relevant to the Treatment of Chronic Myelogenous Leukemia Based on National Comprehensive Network Treatment Guidelines. Clin Lymphoma Myeloma Leuk. 2015;15:797-802 pubmed publisher
    ....
  6. Paul S, Kantarjian H, Jabbour E. Adult Acute Lymphoblastic Leukemia. Mayo Clin Proc. 2016;91:1645-1666 pubmed publisher
    ..These new developments are changing the treatment of adult ALL from a "one therapy fits all" approach to individualized treatment based on patient's cytogenetic and molecular profile. ..
  7. Yilmaz M, Jabbour E. Tyrosine Kinase Inhibitors Early in the Disease Course: Lessons From Chronic Myelogenous Leukemia. Semin Oncol. 2015;42:876-86 pubmed publisher
    ..However, due to lack of long-term outcome data and absence of consensus for the definition of optimal response and time to stop TKIs, discontinuation is discouraged outside of a clinical trial. ..
  8. Jabbour E, Mathisen M, Garcia Manero G, Champlin R, Popat U, Khouri I, et al. Allogeneic hematopoietic stem cell transplantation versus hypomethylating agents in patients with myelodysplastic syndrome: a retrospective case-control study. Am J Hematol. 2013;88:198-200 pubmed publisher
    ..001). These results would suggest that prospective studies are needed to delineate the timing and efficacy of allo-SCT in the HMA era. ..
  9. Jabbour E, Ottmann O, Deininger M, Hochhaus A. Targeting the phosphoinositide 3-kinase pathway in hematologic malignancies. Haematologica. 2014;99:7-18 pubmed publisher
    ..This article reviews the role of phosphoinositide 3-kinase signaling in hematologic malignancies and the potential clinical utility of inhibitors that target this pathway. ..
  10. Assi R, Kantarjian H, Short N, Daver N, Takahashi K, Garcia Manero G, et al. Safety and Efficacy of Blinatumomab in Combination With a Tyrosine Kinase Inhibitor for the Treatment of Relapsed Philadelphia Chromosome-positive Leukemia. Clin Lymphoma Myeloma Leuk. 2017;: pubmed publisher
    ..The combination of blinatumomab with TKI is safe and effective in patients with relapsed/refractory Ph+ disease. Prospective studies are warranted. ..

Detail Information

Publications11

  1. request reprint
    Jabbour E, Soverini S. Understanding the role of mutations in therapeutic decision making for chronic myeloid leukemia. Semin Hematol. 2009;46:S22-6 pubmed
    ..The choice of therapy should be guided by multiple factors, including mutational analysis, disease phase, patient characteristics, and the safety profile of the agents. ..
  2. Jabbour E, Kantarjian H, Ghanem H, O Brien S, Quintas Cardama A, Garcia Manero G, et al. The achievement of a 3-month complete cytogenetic response to second-generation tyrosine kinase inhibitors predicts survival in patients with chronic phase chronic myeloid leukemia after imatinib failure. Clin Lymphoma Myeloma Leuk. 2013;13:302-6 pubmed publisher
    ..The achievement of a 3-month CCyR is the only predictor of outcome in patients treated with 2nd-TKI therapy after imatinib failure. Patients with <3-month CCyR may not obtain long-term benefit and should be followed-up closely. ..
  3. Jabbour E, Kantarjian H, Cortes J. Use of second- and third-generation tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia: an evolving treatment paradigm. Clin Lymphoma Myeloma Leuk. 2015;15:323-34 pubmed publisher
    ..Finally, we present 3 case studies to illustrate how prognostic factors and other considerations (eg, tolerability) can be used to individualize subsequent therapy in cases of TKI resistance or intolerance. ..
  4. Jabbour E, Kantarjian H, Ravandi F, Thomas D, Huang X, Faderl S, et al. Combination of hyper-CVAD with ponatinib as first-line therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia: a single-centre, phase 2 study. Lancet Oncol. 2015;16:1547-1555 pubmed publisher
    ..New strategies, including dosing titration of ponatinib and optimised control of vascular risk factors, might further improve outcomes. ARIAD Pharmaceuticals Inc. ..
  5. Jabbour E, Makenbaeva D, Lingohr Smith M, Lin J. Use of Real-World Claim Databases to Assess Prevalence of Comorbid Conditions Relevant to the Treatment of Chronic Myelogenous Leukemia Based on National Comprehensive Network Treatment Guidelines. Clin Lymphoma Myeloma Leuk. 2015;15:797-802 pubmed publisher
    ....
  6. Paul S, Kantarjian H, Jabbour E. Adult Acute Lymphoblastic Leukemia. Mayo Clin Proc. 2016;91:1645-1666 pubmed publisher
    ..These new developments are changing the treatment of adult ALL from a "one therapy fits all" approach to individualized treatment based on patient's cytogenetic and molecular profile. ..
  7. Yilmaz M, Jabbour E. Tyrosine Kinase Inhibitors Early in the Disease Course: Lessons From Chronic Myelogenous Leukemia. Semin Oncol. 2015;42:876-86 pubmed publisher
    ..However, due to lack of long-term outcome data and absence of consensus for the definition of optimal response and time to stop TKIs, discontinuation is discouraged outside of a clinical trial. ..
  8. Jabbour E, Mathisen M, Garcia Manero G, Champlin R, Popat U, Khouri I, et al. Allogeneic hematopoietic stem cell transplantation versus hypomethylating agents in patients with myelodysplastic syndrome: a retrospective case-control study. Am J Hematol. 2013;88:198-200 pubmed publisher
    ..001). These results would suggest that prospective studies are needed to delineate the timing and efficacy of allo-SCT in the HMA era. ..
  9. Jabbour E, Ottmann O, Deininger M, Hochhaus A. Targeting the phosphoinositide 3-kinase pathway in hematologic malignancies. Haematologica. 2014;99:7-18 pubmed publisher
    ..This article reviews the role of phosphoinositide 3-kinase signaling in hematologic malignancies and the potential clinical utility of inhibitors that target this pathway. ..
  10. Assi R, Kantarjian H, Short N, Daver N, Takahashi K, Garcia Manero G, et al. Safety and Efficacy of Blinatumomab in Combination With a Tyrosine Kinase Inhibitor for the Treatment of Relapsed Philadelphia Chromosome-positive Leukemia. Clin Lymphoma Myeloma Leuk. 2017;: pubmed publisher
    ..The combination of blinatumomab with TKI is safe and effective in patients with relapsed/refractory Ph+ disease. Prospective studies are warranted. ..
  11. Short N, Jabbour E. Minimal Residual Disease in Acute Lymphoblastic Leukemia: How to Recognize and Treat It. Curr Oncol Rep. 2017;19:6 pubmed publisher
    ..Future studies will be required to determine whether these post-remission strategies can obviate the need for allogeneic stem cell transplantation for patients with ALL in whom MRD can be eradicated. ..